<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987855</url>
  </required_header>
  <id_info>
    <org_study_id>RSD-CRPS</org_study_id>
    <nct_id>NCT02987855</nct_id>
  </id_info>
  <brief_title>Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia</brief_title>
  <acronym>ADcSVF-CRPS</acronym>
  <official_title>Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), and Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healeon Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healeon Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and
      disabilities. They are often associated with injury sites (including surgical) which produce
      constant, often disabling pain and motor-sensory losses.

      Treatments are often ineffective and include medications (often high dose opiates), Physical
      Therapy (PT), and surgical interventions (sympathectomy, ablation) or insertion stimulators
      of the CNS.

      Study is an interventional study to document the safety and efficacy of use of
      adipose-derived cellular stromal vascular fraction (AD-cSVF) in chronic pain and dysfunction
      disease groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and
      disabilities. They are often associated with injury sites (including surgical) which produce
      constant, often disabling pain and motor-sensory losses.

      Treatments are often ineffective and include medications (often high dose opiates), physical
      therapy (PT(, and surgical interventions (sympathectomy, ablation) or insertion stimulators
      of the CNS.

      Clinical Features include neurogenic inflammation, nociceptive sensitization, vasomotor
      dysfunction and maladaptive neuroplasticity. As these often seem related to specific injury
      sites (trauma, surgical, etc.) which are followed with severe pain sensations such as
      stabbing, burning, throbbing, and local muscular spasms or hemiparesis. In addition, there
      are many reports of visual change, dropping attacks (sudden falling), joint soreness, and
      other systemic symptoms associated with potentially any organ in the body.

      Diagnosis typically recognizes 3 distinct &quot;types&quot; which do not appear to be sequential in
      nature. Type 1 characterization is severe, burning sensory change near an injury site,
      musculoskeletal and joint stiffness. Type 2 demonstrates very high pain levels, swelling,
      muscular atrophy, joint degeneration, depression, and other concomitant dysfunctions. Type 3
      features irreversible changes to skin/bone, and extreme loss of function of muscle (atrophic
      primarily) and tendons. A significant percentage (13-70 ) are felt to be at risk if
      neurological injuries, hemiplegia, enhanced vasomotor issues due to enhanced sympathetic
      actions and neurotransmission issues.

      This study includes microcannula harvesting of subdermal adipose tissues, incubation,
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured
      at intervals (both severe and non-severe categories) and by repeated pulmonary function
      studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse and Severe Adverse Reaction Report</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate any Adverse or Severe Adverse Reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Pain Levels</measure>
    <time_frame>1 month, 6 month, 1 year</time_frame>
    <description>Pain Scale Questionnaire 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life from Baseline</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Quality of Life Questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Lifestyle</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Fibromyalgia Impact Questionnaire (FIQR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>RSD (Reflex Sympathetic Dystrophy)</condition>
  <condition>CRPS - Complex Regional Pain Syndrome Type I</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline IV with AD-cSVF cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipoaspiration</intervention_name>
    <description>Closed syringe harvesting subdermal fat</description>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADcSVF isolation</intervention_name>
    <description>Isolation of AD-cSVF from lipoaspirate via enzymatic digestion</description>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline IV</intervention_name>
    <description>Normal Saline IV containing autologous AD-cSVF</description>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of RSD, CRPS, and severe Fibromyalgia

          -  Ability to provide Informed Consent (or as parent or legal guardian)

        Exclusion Criteria:

          -  Patients with severe comorbidities which, in opinion of PI or provider associates.
             would be unsafe or not advised to be able to comply with study or follow up
             requirements

          -  Patients with documented Opiate abuse

          -  Patient taking corticosteroid therapy, immune suppression, or chemotherapeutic regimen
             within 6 months of entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn C Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Alliance for Regenerative Medicine (GARM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert W Alexander, MD</last_name>
    <phone>406.777.5312</phone>
    <email>rwamd@cybernet1.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Riley, CMA</last_name>
    <phone>406.777.5312</phone>
    <email>irbtrials1@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regenevita LLC</name>
      <address>
        <city>Stevensville</city>
        <state>Montana</state>
        <zip>59870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Riley, CMA</last_name>
      <phone>406-777-5312</phone>
      <email>irbtrials1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nancy L Smith, MA,ORT</last_name>
      <phone>406777.5312</phone>
      <email>nancy@cybernet1.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GARM</name>
      <address>
        <city>Roatan</city>
        <state>HN</state>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn C Terry, MD</last_name>
      <phone>+1.765.669.9141</phone>
      <email>corky3444@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Terry</last_name>
      <phone>17065669141</phone>
      <email>info@garm.com.hn</email>
    </contact_backup>
    <investigator>
      <last_name>Glenn C Terry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert W Alexander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May;25(4):273-80. doi: 10.1097/AJP.0b013e31818ecea5.</citation>
    <PMID>19590474</PMID>
  </reference>
  <reference>
    <citation>Marinus J, Moseley GL, Birklein F, Baron R, Maihöfner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011 Jul;10(7):637-48. doi: 10.1016/S1474-4422(11)70106-5. Review.</citation>
    <PMID>21683929</PMID>
  </reference>
  <reference>
    <citation>Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23;342(8878):1012-6.</citation>
    <PMID>8105263</PMID>
  </reference>
  <reference>
    <citation>Maihöfner C, Forster C, Birklein F, Neundörfer B, Handwerker HO. Brain processing during mechanical hyperalgesia in complex regional pain syndrome: a functional MRI study. Pain. 2005 Mar;114(1-2):93-103. Epub 2005 Jan 26.</citation>
    <PMID>15733635</PMID>
  </reference>
  <reference>
    <citation>Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med. 2005 Feb;257(2):139-55. Review.</citation>
    <PMID>15656873</PMID>
  </reference>
  <reference>
    <citation>Birklein F. Complex regional pain syndrome. J Neurol. 2005 Feb;252(2):131-8. Review.</citation>
    <PMID>15729516</PMID>
  </reference>
  <reference>
    <citation>Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, Sullivan P, Meier P, Zurakowski D, Masek BJ, Berde CB. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002 Jul;141(1):135-40.</citation>
    <PMID>12091866</PMID>
  </reference>
  <reference>
    <citation>van de Meent H, Oerlemans M, Bruggeman A, Klomp F, van Dongen R, Oostendorp R, Frölke JP. Safety of &quot;pain exposure&quot; physical therapy in patients with complex regional pain syndrome type 1. Pain. 2011 Jun;152(6):1431-8. doi: 10.1016/j.pain.2011.02.032. Epub 2011 Apr 6.</citation>
    <PMID>21474244</PMID>
  </reference>
  <reference>
    <citation>Swart CM, Stins JF, Beek PJ. Cortical changes in complex regional pain syndrome (CRPS). Eur J Pain. 2009 Oct;13(9):902-7. doi: 10.1016/j.ejpain.2008.11.010. Epub 2008 Dec 19. Review.</citation>
    <PMID>19101181</PMID>
  </reference>
  <reference>
    <citation>Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.</citation>
    <PMID>23546884</PMID>
  </reference>
  <reference>
    <citation>Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs. 2012 Mar 1;26(3):215-28. doi: 10.2165/11595200-000000000-00000. Review.</citation>
    <PMID>22136149</PMID>
  </reference>
  <reference>
    <citation>Opal SM, Wiest PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. R I Med J. 1990 May;73(5):199-204.</citation>
    <PMID>2343234</PMID>
  </reference>
  <reference>
    <citation>Varenna M, Adami S, Rossini M, Gatti D, Idolazzi L, Zucchi F, Malavolta N, Sinigaglia L. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2013 Mar;52(3):534-42. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30.</citation>
    <PMID>23204550</PMID>
  </reference>
  <reference>
    <citation>Gainer MJ. Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn. 1992 Apr;34(4):227-32.</citation>
    <PMID>1349789</PMID>
  </reference>
  <reference>
    <citation>Hamdi TN. The Copeland intraocular lens: five to ten years later. Ophthalmology. 1979 Jun;86(6):984-96.</citation>
    <PMID>534104</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>September 10, 2017</last_update_submitted>
  <last_update_submitted_qc>September 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healeon Medical Inc</investigator_affiliation>
    <investigator_full_name>Robert W. Alexander, MD, FICS</investigator_full_name>
    <investigator_title>Principal Investigator, Science</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

